Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab.
Miguel A
MA
Pérez-Valdivia
Manuel
M
López-Mendoza
Francisco J
FJ
Toro-Prieto
Virginia
V
Cabello-Chaves
Mercedes
M
Toro-Ramos
M Carmen
MC
Martín-Herrera
Luis
L
Gómez-García
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009402:Nephrosis, Lipoid / Q000139:chemically induced*; D012008:Recurrence
D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab